Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Chinese Academy of Medical Sciences & Peking Union Medical College logo

Chinese Academy of Medical Sciences & Peking Union Medical College

Status and phase

Unknown
Phase 2

Conditions

Toripalimab
Diffuse Large B-cell Lymphoma
Rituximab

Treatments

Drug: Toripalimab combine with Rituximab

Study type

Interventional

Funder types

Other

Identifiers

NCT04425824
NCC2244

Details and patient eligibility

About

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.

Full description

Toripalimab is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Rituximab is an antibody to CD20 molecules. One of the mechanisms of killing tumor cells is through antibody-dependent cell-mediated cytotoxicity (ADCC). These two drugs may have a synergistic effect on anti-tumor. The purpose of this study is to determine whether Toripalimab with Rituximab is effective and safe for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma. This is an exploratory small sample, phase II, single-center clinical trial, which is going to enroll 20 participants.

Enrollment

20 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age ≥18 years old;

  2. According to the WHO 2016 classification criteria, the CD20 positive diffuse large B-cell lymphoma (DLBCL) diagnosed by pathology should include the indicators of immunohistochemistry: CD10, BCL-2, MUM-1, BCL-6 and C-MYC;

  3. Relapsed or refractory DLBCL.Patients younger than 65 years should relapse or progress after receiving at least second-line treatment, and patients 65 years of age and older could be intolerant to second-line treatment, and they who relapse or progress after receiving first-line treatment;

  4. There is at least one measurable lesion, defined as measurable dual-diameter, intra-lymph node lesion, short diameter> 1.5cm, extra-lymph node lesion short diameter> 1.0cm;

  5. Recurrence confirmed by pathological biopsy and CD20 positive;

  6. ECOG score 0-2 points;

  7. No autoimmune diseases;

  8. Blood routine examination meets the following criteria:

    1. Neutrophil count ≥ 1.5 x 109 / L,;
    2. Platelet ≥ 75 x 109 / L,;
    3. Hemoglobin ≥ 10.0 g / dL;
  9. The main organ function meets the following criteria:

    1. Aspartate aminotransferase and alanine aminotransferase ≤ 2.0 times the upper limit of normal value;
    2. Bilirubin ≤ 2.0 mg / dL;
    3. Creatinine clearance rate ≥ 60 mL / min;
  10. Patients must agree to take effective contraceptive measures during the study according to the investigator's request;

  11. Understand and voluntarily sign written informed consent.

Exclusion criteria

  1. Diagnosed as transformed diffuse large B-cell lymphoma;
  2. Diagnosed as double-hit diffuse large B-cell lymphoma (DHL);
  3. Diagnosed as primary or secondary central nervous system lymphoma;
  4. HBV DNA positive or HCV RNA positive patients;
  5. Left ventricular ejection fraction <50%;
  6. Patients with history of autoimmune diseases, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome, ankylosing spondylitis
  7. Patients are using or have been used immunosuppressive drugs
  8. Patients with ≥2 grade peripheral neuropathy

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Toripalimab combine with Rituximab
Experimental group
Description:
Experimental: Toripalimab combine with Rituximab Induction period: Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles. Rituximab 375mg/m² administered intravenously (IV) on Day 1 of each 21-day cycle for 6 cycles. Maintenance: Toripalimab 240mg administered intravenously (IV) and Rituximab 375mg/m² on Day 1 of each 56-day cycle for 6 cycles.
Treatment:
Drug: Toripalimab combine with Rituximab

Trial contacts and locations

1

Loading...

Central trial contact

Yan Qin, doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems